Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease

Type 2 Diabetes Clinical Trial

Official title:

A Randomized Double-Blind Controlled Study Comparing the Effects of Probiotic Adjuvant Therapy on the Improvement of Lung Function and Blood Sugar in Patients With Type 2 Diabetes and Chronic Obstruction Pulmonary Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05492448
• Other study ID #: EMRP12110N
• Status: Recruiting
• Phase: N/A
• Start date: September 19, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: February 2024
• Source: Glac Biotech Co., Ltd
• Contact: Yu-Feng Wei, M.D., Ph.D
• Phone: 886-7-6150011
• Email: yufeng528[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial is a randomized, double-blind, parallel placebo clinical trial, the purpose of which is to investigate whether the adjuvant therapy of using probiotics during the treatment of diabetic patients can decrease blood sugar levels significantly in comparison with placebo, and observe if the reduced lung function could be recovered in patients with type 2 diabetes (T2DM) and chronic obstructive pulmonary disease (COPD) simultaneously.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: December 31, 2024
• Est. primary completion date: February 22, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 85 Years

Eligibility

Inclusion Criteria:

• Subjects are between 50-85 years old, and clinical diagnosis of T2DM (HbA1c = 6.5% or fasting plasma glucose = 126 mg/dL or oral glucose tolerance test 2-hour plasma glucose = 200 mg/dL).

• Patients with stable pulmonary obstruction (pulmonary function FEV1/FVC <0.7) with symptoms of pulmonary obstruction.

• Subjects can cooperate with the collection of experimental specimens and return for regular visits.

• The patient or family members have signed the informed consent form.

• The patient must receive adjuvant treatment with probiotic for 12 weeks.

Exclusion Criteria:

• The patient or caregiver is unable to follow the physician's instructions for the trial, including the completed symptom assessment form and compliance with medication.

• The patient has a history of related allergic reactions, or the use of other highly sensitive or contraindicated drugs (Allergy to antibiotics or antipyretics).

• The patient have taken oral immunosuppressive drugs, intravenous steroids or T cell inhibitor ointments within the past 2 weeks.

• The patient has consumed probiotic-related products (including drops, lozenges, capsules, powder and yogurt) within the past 1 month.

• The patient received high doses of steroids within the past 1 month.

• The patient with active infection or severe pulmonary disease (eg, tuberculosis, bronchiectasis, or fibrosis).

• The patient is receiving treatment for a major disease or congenital disease.

• The patient is not suitable to participate in the trial as assessed by the professional physician.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive
• Type 2 Diabetes

Intervention

Dietary Supplement:
• Placebo
Subjects take one pack containing maltodextrin twice daily after breakfast and dinner.
• L. salivarius AP-32 and L. reuteri GL-104
Subjects take one pack containing L. salivarius AP-32 and L. reuteri GL-104 twice daily after breakfast and dinner.
• L. reuteri GL-104
Subjects take one pack containing L. reuteri GL-104 twice daily after breakfast and dinner.

Locations

Country	Name	City	State
Taiwan	Glac Biotech Co., Ltd.	Tainan City

Sponsors (1)

Lead Sponsor	Collaborator
Glac Biotech Co., Ltd

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in concentration of glycated hemoglobin (HbA1c).	Changes in concentration of HbA1c were assessed before and after 4-, 12-week intervention.	Before and after 4-, 12-week intervention.
Primary	Changes in ratio of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC).	Changes in ratio of FEV1/FVC were assessed by bronchodilator test before and after 4-, 12-week intervention.	Before and after 4-, 12-week intervention.
Secondary	Changes in concentration of fasting blood sugar.	Changes in concentration of fasting blood sugar were assessed before and after 4-, 12-week intervention.	Before and after 4-, 12-week intervention.
Secondary	Changes in concentration of immune cytokines.	Changes in concentration of immune cytokines were assessed before and after 4-, 12-week intervention.	Before and after 4-, 12-week intervention.
Secondary	Changes in scores of modified medical research council (mMRC).	Changes in scores of mMRC were assessed before and after 4-, 12-week intervention. The minimum score is 0 and the maximum score is 4. A higher score means more difficult breathing.	Before and after 4-, 12-week intervention.
Secondary	Changes in scores of COPD assessment test (CAT).	Changes in scores of CAT were assessed before and after 4-, 12-week intervention. The minimum score is 0 and the maximum score is 40. A higher score means more seriously affect life.	Before and after 4-, 12-week intervention.
Secondary	Changes of the composition in gut microbiota.	Changes of the composition in gut microbiota were analyzed by next-generation sequencing (NGS) before and after 12-week intervention.	Before and after 12-week intervention.
Secondary	Changes of the composition in lower respiratory tract microbiota.	Changes of the composition in lower respiratory tract microbiota were analyzed by next-generation sequencing (NGS) before and after 12-week intervention.	Before and after 12-week intervention.
Secondary	Changes of concentration in short-chain fatty acid (SCFA) on plasma.	Changes of concentration in SCFA on plasma were analyzed by gas chromatography-mass spectrometry before and after 12-week intervention.	Before and after 12-week intervention.
Secondary	Changes of concentration in short-chain fatty acid (SCFA) on stool.	Changes of concentration in SCFA on stool were analyzed by gas chromatography-mass spectrometry before and after 12-week intervention.	Before and after 12-week intervention.
Secondary	Changes in scores of modified Bristol stool form scale.	Changes in scores of modified Bristol stool form scale were assessed before and after 4-, 12-week intervention. The questionnaire included the stool form [1 = very hard (small hard lumps), 2 = hard stool (hard sausage shape), 3 = normal stool (sausage to banana shape), 4 = soft stool, 5 = muddy stool, 6 = watery stool], ease of defecation (1 = difficult, 2 = easy, 3 = very easy) and abdominal symptoms [frequency of upper abdominal pain, lower abdominal pain, borborygmus, and flatulence (1 = frequent, 2 = occasional, 3 = almost never)].	Before and after 4-, 12-week intervention.